文献速递肿瘤 PET/CT

基线临床数据、肿瘤代谢与肿瘤血流在新辅助化疗后预测HER2和三阴性乳腺癌病理完全缓解中的各自贡献

Respective contribution of baseline clinical data, tumour metabolism and tumour blood-flow in predicting pCR after neoadjuvant chemotherapy in HER2 and Triple Negative breast cancer.
PubMed 文献 · EJNMMI Res · 2024-07-04

该研究纳入128例未经治疗的乳腺癌患者,在治疗前行18F-FDG PET/CT,从首次通过动态和延迟PET图像提取肿瘤血流(BF)和代谢参数(含纹理特征),结合临床参数构建模型预测新辅助化疗(NAC)后的病理完全缓解(pCR)。结果显示,在全数据集及三阴性(TN)亚组中,临床+代谢(C+M)模型预测表现优于临床(C)模型,而加入BF参数未改善预测;在HER2亚组中C与C+M模型表现相当。

要点

  • 全数据集中C+M模型平衡准确率0.66,显著高于C模型的0.61(P<0.01),也优于C+M+BF模型的0.64。
  • TN亚组C+M模型平衡准确率0.65,优于C的0.63和C+M+BF的0.62,但差异未达统计学显著。
  • HER2亚组C与C+M模型表现相当,均高于C+M+BF模型(平衡准确率0.64 vs 0.61)。

核心结论

  • 基线临床数据联合18F-FDG PET/CT全局及纹理肿瘤代谢参数,在TN亚组及HER2与TN全数据集中对NAC后pCR的预测优于单独临床参数。
  • 将BF参数加入模型未改善预测,无论分析哪个肿瘤亚组。

研究设计与样本

  • 研究纳入128例新诊断乳腺癌患者,在任何治疗前行18F-FDG PET/CT。
  • 从首次通过动态和延迟PET图像分别提取肿瘤BF和代谢参数,并提取标准及纹理特征。
  • 采用逻辑回归、随机森林和支持向量分类算法构建模型,算法在80%数据集训练、剩余20%测试,共进行50次随机拆分。
  • 分析在全数据集(HER2与TN)及HER2(N=76)和TN(N=52)亚组中分别进行。

主要发现

  • 全数据集中C+M模型平均平衡准确率0.66,显著高于C模型的0.61(P<0.01),并优于C+M+BF模型的0.64。
  • HER2亚组中C与C+M模型表现相当,均高于C+M+BF模型(平均平衡准确率0.64 vs 0.61)。
  • TN亚组中C+M模型平均平衡准确率0.65,优于C的0.63和C+M+BF的0.62,但差异未达统计学显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study is to investigate the added value of combining tumour blood flow (BF) and metabolism parameters, including texture features, with clinical parameters to predict, at baseline, the pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in patients with newly diagnosed breast cancer (BC). METHODS: One hundred and twenty-eight BC patients underwent a 18F-FDG PET/CT before any treatment. Tumour BF and metabolism parameters were extracted from first-pass dynamic and delayed PET images, respectively. Standard and texture features were extracted from BF and metabolic images. Prediction of pCR was performed using logistic regression, random forest and support vector classification algorithms. Models were built using clinical (C), clinical and metabolic (C+M) and clinical, metabolic and tumour BF (C+M+BF) information combined. Algorithms were trained on 80% of the dataset and tested on the remaining 20%. Univariate and multivariate features selections were carried out on the training dataset. A total of 50 shuffle splits were performed. The analysis was carried out on the whole dataset (HER2 and Triple Negative (TN)), and separately in HER2 (N=76) and TN (N=52) tumours. RESULTS: In the whole dataset, the highest classification performances were observed for C+M models, significantly (p-value<0.01) higher than C models and better than C+M+BF models (mean balanced accuracy of 0.66, 0.61, and 0.64 respectively). For HER2 tumours, equal performances were noted for C and C+M models, with performances higher than C+M+BF models (mean balanced accuracy of 0.64, and 0.61 respectively). Regarding TN tumours, the best classification results were reported for C+M models, with better performances than C and C+M+BF models but not significantly (mean balanced accuracy of 0.65, 0.63, and 0.62 respectively). CONCLUSION: Baseline clinical data combined with global and texture tumour metabolism parameters assessed by 18F-FDG PET/CT provide a better prediction of pCR after NAC in patients with BC compared to clinical parameters alone for TN, and HER2 and TN tumours together. In contrast, adding BF parameters to the models did not improve prediction, regardless of the tumour subgroup analysed.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Payan N, Presles B, Coutant C, et al. Respective contribution of baseline clinical data, tumour metabolism and tumour blood-flow in predicting pCR after neoadjuvant chemotherapy in HER2 and Triple Negative breast cancer. EJNMMI Res. 2024. PMID: 38965124. doi:10.1186/s13550-024-01115-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。